Opioid dependence represents a public health crisis and can be observed after outpatient urologic procedures. The purpose of this study was to evaluate the risk of persistent opioid usage after radical orchiectomy for testicular cancer.
The TriNetX Research network database was queried for men between 15 and 45 years undergoing radical orchiectomy for a diagnosis of testicular cancer. All patients with N+ or M+ disease, prior opioid use, and patients who underwent chemotherapy, radiotherapy, or retroperitoneal lymph node dissection were excluded. Patients were stratified whether they were prescribed opioids or not at time of orchiectomy. The incidence of new, persistent opioid use, defined as a prescription for opioids between 3 and 15 months after orchiectomy, was evaluated.
A total of 2,911 men underwent radical orchiectomy for testicular cancer, of which 89.8% were prescribed opioids at time of orchiectomy. After propensity score matching for age, race, and history of psychiatric diagnosis, 592 patients were included (296 received opioids, 296 did not). Overall, 0% of patients who did not receive postoperative opioids developed new persistent opioid use, whereas 10.5% of patients who received postoperative opioids developed new persistent opioid use. Patients prescribed postoperative opioids for orchiectomy had statistically higher risk difference of developing new persistent opioid use (Risk Difference: 10.5%; 95% CI: 7.0-14.0; Z: 5.7; P < 0.01).
Postoperative opioid prescription following radical orchiectomy is significantly associated with developing new persistent opioid use, with 1 in 10 young men who received postoperative opioids obtaining a new prescription for opioids well beyond the postoperative period. Future efforts should emphasize nonopioid pathways for pain control following this generally minor procedure.
Urologic oncology. 2024 Aug 02 [Epub ahead of print]
Muhannad Alsyouf, Ala'a Farkouh, Erika L Wood, Alireza Ghoreifi, Antoin Douglawi, Martin Hofmann, Brian Hu, Anne Schuckman, Hooman Djaladat, Siamak Daneshmand
Department of Urology, Loma Linda University Health, Loma Linda, CA; Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Department of Urology, Riverside University Health System, Moreno Valley, CA. Electronic address: ., Department of Urology, Loma Linda University Health, Loma Linda, CA., Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.